Business Wire

CHRYSO

9.9.2020 15:12:38 CEST | Business Wire | Press release

Share
CHRYSO and SOLIDIA Partner to Deploy Ultra-low CO2 Concrete

CHRYSO, a world leader in construction chemicals, today announces its partnership with Solidia Technologies, a start-up inventor of revolutionary technology for green cement and concrete. The two companies will collaborate to improve the sustainability performance and material properties of Solidia® ultra-low CO2 concrete through their combined chemical expertise.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200909005655/en/

The partnership is underpinned by a long-term commitment from both companies to making sustainable solutions accessible to cement and concrete producers worldwide.
Solidia® sustainable technology is already available in the precast market and used for non-reinforced concrete elements. Solidia’s unique technologies are based on a revolutionary cement chemistry that can be produced at lower energies, significantly lowering carbon emissions, and that does not hydrate but carbonates by injection of CO2 into fresh concrete. Combined, Solidia’s processes lower the carbon footprint of concrete by up to 70%, while reducing water and energy consumption. They also improve the performance and durability of concrete, which are further enhanced with new, sophisticated admixture solution.
CHRYSO draws on a solid knowledge of sustainable building materials. For more than 10 years, the company has been developing admixture solutions that allow the intensive use of alternative binders without compromising material performance.

“The development of innovative admixture solutions adapted to Solidia’s new binder, boosting the final properties of concrete, is one of our R&D works in progress. This will enable higher strengths, an improved finish of the fresh concrete, and the optimization of the curing process. Together with Solidia, we will scale the use of low CO2 concrete, helping manufacturers produce high quality precast elements,” declared Jean Mascaro, Concrete BU director of CHRYSO.

Tom Schuler, president and CEO of Solidia Technologies , said: “Incorporating CHRYSO® ’s exclusive water-reducing admixtures adapted to the specific chemistry of Solidia Concrete™, will further reduce water consumption in the curing process.”
A key objective for the start-up is to improve cement and concrete production and performance while enhancing its environmental impact. Tom Schuler added: “By cutting energy consumption during the curing process, CHRYSO will help us achieve our ambitions and reach higher levels of performance.”

This partnership paves the way for upcoming advances in CO 2 footprint reduction and new developments in sustainable chemistry. The deployment of new ultra-low C0 2 concrete will accelerate the decarbonization of the construction industry.

About the CHRYSO Group
Aimed at cement manufacturers, ready-mix concrete and precast industrials, and construction companies, CHRYSO's offer includes cement additives, concrete admixtures and Solutions for Construction Systems (waterproofing solutions, mortars, etc.). CHRYSO® solutions have won renown on the most prestigious construction sites throughout the world thanks to the group's extensive network, which includes 22 foreign subsidiaries and covers more than 100 countries through its wide network of distributors, licensees and agents. The CHRYSO group employs over 1,300 staff worldwide. Innovation, customer service, expertise and technical know-how are the CHRYSO Group's cornerstones. More info about CHRYSO: www.chryso.com

About Solidia Technolgies
Solidia Technologies® is a cement and concrete technology company that makes it easy and profitable to use CO2 to manufacture superior, sustainable building materials. Each year, Solidia can eliminate at least 1.5 Gt of CO₂, save 3 trillion liters of fresh water, reduce cement industry energy consumption by 67 Mt of coal, and eliminate 100 Mt of concrete waste landfill. Produced using the same raw materials and existing equipment, Solidia products are higher performing and cost less to produce than traditional concrete, and cure in less than 24 hours. Solidia offers a rapid, globally scalable response to one of the greatest threats to our planet.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release

Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna

Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release

Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye